DBV Technologies at EAACI Congress 2025

“`html

Dbv Technologies To Present Viaskin® Peanut Patch Data At Eeaci 2025

Châtillon, France – June 12, 2025 – Dbv Technologies (Euronext: dbv – Isin: Fr0010417345 – Nasdaq: Dbvt), A Clinical-Stage Biopharmaceutical Company, Announced Its Participation In The European Academy Of Allergy and Clinical Immunology (Eeaci) Congress In Glasgow, Uk.

The Company Will Present New Data On The viaskin® Peanut Patch, An Innovative Approach To Treating Peanut Allergies, Offering Hope For Millions Worldwide.

Key Highlights of Dbv Technologies At Eaaci 2025

Dbv technologies Is Set to Showcase Significant Findings Related To Its Viaskin® Peanut Patch At The Upcoming Eeaci 2025 Congress. This Includes Data From The Open Extension Study (Ole) Of Epitope, Highlighting The Reduction In Reaction Rates During Accidental Peanut Consumption (Caa) With The Viaskin® Peanut Patch Compared To Placebo.

Additionally, Results From The Phase 2 Aptitude Study, Conducted With Nestle Health Science, Will Be Presented, Focusing On The Sensitivity, Specificity, And Safety Of A Viaskin® Patch (Dbv1605) For Diagnosing Non-Ige-Mediated Cow’s Milk Allergy In Infants. These Presentations Are Expected To Draw Considerable Attention From Allergists And Immunologists Globally.

Symposium: Peanut Allergy – Recent Research Highlights

The Dbv Symposium, Titled “Peanut Allergy: Recent Research Highlights,” Will Feature Leading Experts Discussing The Latest Advancements In Peanut Allergy Treatment. Co-Chaired By Professor Gideon Lack And Professor Alexandra Santos, The Symposium Will Include Presentations On The Clinical Relationship Between Patients With Food Allergies And Allergists, Presented By Ozlem Ceylan And Professor Sophia Tsabouri.

Professor Katharina Blümchen Will Also Present New Clinical Data On Epicutaneous immunotherapy For Peanut Allergy. This symposium Aims To Provide New Perspectives on Epicutaneous Immunotherapy In Peanut Allergy, With An Interactive Discussion Illustrating The clinical Relationship Between An Allergist And Patient.

Detailed Scientific Presentations

Dr. Jay A. Lieberman Will Present Data On The “Real-World Protective Effects of Epicutaneous Immunotherapy In Peanut-Allergic Toddlers.” This Session Will Detail Findings From The Second Year Of The Epitope Study’s Open Extension, Demonstrating A Reduction In Caa Reactions With Increased Treatment Duration.

Professor Roberto Berni-Cananani will Present The “Phase 2 Study To Evaluate The Sensitivity, Specificity, And Safety Of Dbv1605 As A Diagnostic Tool For Non-Ige-Mediated Cow’s Milk allergy In Children (Aptitude).” Despite Premature Judgment Due To Recruitment Difficulties, The Study provides Encouraging Insights Into the Potential Of The Viaskin® Patch In Diagnosing Food Allergies.

“We Are Eager To Share New clinical Data From The Second Year Of The Epitope Study’s Open Extension, Which Highlights The Real-life Protective Effects Of The Viaskin® Peanut Patch In one-To-Three-Year-Olds Allergic To Peanuts,” Said Dr. Pharis Mohideen, Chief Medical Officer At Dbv Technologies.

Viaskin® Patch: A Potential Game-Changer For Food Allergies

The Viaskin® Patch Represents A Novel Approach To Treating Food Allergies Through epicutaneous Immunotherapy (Epit™). This Method Delivers Microgram Quantities Of allergen To The Immune System Via Intact Skin, Aiming To Resensitize The Body And reduce Allergic Reactions. The Patch Is Designed To Be Non-Invasive, Offering A Convenient Alternative To Traditional Immunotherapy Methods.

Dbv Technologies Is Committed To Transforming The Treatment Of Food Allergies, Notably In Young Children. The Ongoing Clinical Studies With The Viaskin® Peanut Patch in Children Aged 1 To 7 Years Highlight The Company’s Dedication To Addressing This Significant Unmet Medical Need.

Study	Focus	Key Finding
Epitope Ole	Peanut allergy Treatment	Reduction In Caa Reactions With Viaskin® Peanut patch
Aptitude (Phase 2)	Cow’s Milk Allergy Diagnosis	Viaskin® Patch (Dbv1605) Shows Promising Diagnostic Potential

Pro Tip: Always Consult With A Board-Certified Allergist Before Starting Any New Allergy Treatment. Early Diagnosis and Intervention Can Substantially Improve outcomes For Children With Food Allergies.

What does This Mean For The Future Of allergy Treatment?

The Data Presented At Eeaci 2025 Could Signify A Shift In How Peanut Allergies Are Managed, Offering A More Convenient And Perhaps More Effective Treatment Option For Young Children. If Approved, The Viaskin® Peanut Patch could Reduce The Anxiety Associated With Accidental Peanut Exposure.

Dbv Technologies Continues To Advance Its Research And Development Efforts, Aiming To Provide Innovative Solutions For Individuals Living With Food Allergies. Stay Tuned For More Updates As The Eeaci Congress Unfolds.

Did You know? Food Allergies Affect Millions Of People worldwide, With Peanut allergy Being One Of The Most Common And Potentially Severe. The Viaskin® Patch Aims To Address This Critical Need With A Non-Invasive Approach.

want To Learn More?

For More Information, Visit Www.Dbv-Technologies.Com And Follow Dbv Technologies On X (Formerly Twitter) And LinkedIn.

The Growing Need For Effective peanut Allergy Treatments

The Prevalence Of Peanut Allergies Has Been Increasing Over The Past Few Decades, Making It A Significant Public Health Concern. According To Recent Studies, Approximately 2.5% Of Children in The United States Have A peanut Allergy, And This Number Continues To Rise.

Traditional Management Strategies For Peanut Allergies Involve Strict Avoidance Of Peanuts And Carrying Epinephrine Auto-Injectors For Emergency Treatment Of Anaphylaxis. While These Measures Are Essential, They Can be Restrictive And Impact The Quality Of Life For Both Children And Their Families.

Emerging Therapies Like Epicutaneous Immunotherapy (Epit), As Utilized In The Viaskin® Peanut Patch, Offer A Promising Alternative Approach. Epit Aims To Desensitize The Immune System By Gradually Introducing small Amounts Of Peanut Protein Through The Skin, Potentially Reducing The Severity Of Allergic reactions Over time.

The Viaskin® Peanut Patch Is Currently Under Review By regulatory Agencies, And Its Potential Approval could represent A Significant Advancement In The Treatment Of Peanut allergies. Ongoing Clinical Trials Are Further Evaluating Its Efficacy And safety In Different Age Groups And Populations.

The development Of New And Effective Peanut Allergy Treatments Is Crucial To Improve The Lives Of Millions Of Individuals And Families Affected By This Condition. Innovations Like The Viaskin® Patch Offer Hope For A Future Where Peanut Allergies Can Be Better Managed And Controlled.

Frequently Asked Questions About The Viaskin® Peanut Patch